SMARCA2 and breast cancer: Treatment of breast cancer cells with estrogen antagonists induced a temporal association between prohibitin and its co-repressors (Brg1, Brm), which correlates with the recruitment of Brg1 and Brm to endogenous E2F-responsive promoters.